Philogen
Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company developing targeted cancer therapeutics — immunocytokines, radiopharmaceuticals, and DNA-encoded library-derived agents — and licensing them to global pharma partners including Bristol-Myers Squibb, Pfizer, AbbVie, and Janssen.
- Company typePublic
- Founded1996
- HeadquartersSovicille, Italy
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Philogen does
Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company founded in 1996 and listed on the Italian Stock Exchange, with operations centered in Sovicille and Monteriggioni (Italy) and a Swiss research subsidiary, Philochem AG. The company develops targeted cancer therapeutics built on three platform technologies: antibody-cytokine fusion proteins (immunocytokines such as L19IL2/Darleukin and L19TNF/Fibromun), DNA-encoded self-assembling chemical libraries for ligand discovery, and small-molecule radiopharmaceutical conjugates (OncoFAP, OncoACP3, OncoCAIX) for imaging and therapy. Its clinical pipeline addresses soft tissue sarcoma, melanoma, prostate cancer, renal cell carcinoma, and additional solid tumor indications, with Nidlegy (a L19IL2/L19TNF combination) at the most advanced regulatory stage.
The business model combines proprietary pipeline development with strategic out-licensing to global pharmaceutical partners. Revenue is generated through upfront payments, development milestones, and royalties rather than direct product sales — the OncoACP3 prostate cancer radiopharmaceutical was licensed to RayzeBio (Bristol-Myers Squibb) in 2025 for a potential value of up to $1.35 billion plus royalties. Long-standing collaborations with Pfizer, Boehringer Ingelheim, AbbVie, and Janssen Biotech underpin the co-development strategy, while two GMP manufacturing sites in Italy support clinical supply and partner needs. The customer base is structurally Big Pharma, with downstream oncology hospitals and patients reached indirectly through partner commercialization.
Financially, the company reported a H2 2025 net profit of EUR 230 million and EUR 380 million in cash reserves, and the most recent fiscal year reflects a steep revenue and earnings inflection consistent with a major milestone-driven event. Co-founders Dario Neri, Giovanni Neri, and Duccio Neri (CEO and President) remain actively engaged, and the scientific leadership has been externally validated through an ERC Advanced Grant and the Swiss Chemical Society's 2026 Industrial Science Award.
Philogen firmographics
Firmographics- Name
- Philogen
- Legal name
- Philogen S.p.A.
- Website
- https://philogen.com
- Company type
- Public
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Philogen S.p.A. is a Swiss-Italian clinical-stage biotechnology company developing targeted cancer therapeutics — immunocytokines, radiopharmaceuticals, and DNA-encoded library-derived agents — and licensing them to global pharma partners including Bristol-Myers Squibb, Pfizer, AbbVie, and Janssen.
- Ownership category
- akta.pro rank
Philogen industry classification
Industry- Product category
- Targeted Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Philogen is headquartered
LocationHeadquarters
- HQ city
- Sovicille
- HQ country
- Italy
- HQ region
- Europe
Offices3 records
Markets served
Philogen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Licensing and Royalties: Philogen generates revenue through licensing agreements with pharmaceutical companies, including upfront payments, milestone payments, and ongoing royalties. Examples include the Pfizer ADC partnership and the RayzeBio/BMS OncoACP3 deal valued at up to $1.35 billion plus royalties.
- Strategic Research Partnerships: Revenue from collaborative research agreements with pharmaceutical partners including Boehringer Ingelheim, AbbVie, and Janssen Biotech for co-development of therapeutic candidates.
- Pipeline Product Development: Development and potential commercialization of proprietary therapeutic candidates including Nidlegy, Fibromun, and other immunocytokine/radiopharmaceutical products targeting cancer.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Philogen product offering
Product offeringCore offering
Philogen is a clinical-stage biotechnology company that discovers, develops, and manufactures targeted cancer therapeutics based on immunocytokines (antibody-cytokine fusion proteins), DNA-encoded chemical library-derived small molecules, and radiopharmaceuticals. Its pipeline products (Nidlegy, Fibromun, Darleukin, Dodekin, Dekavil, OncoFAP, OncoACP3, OncoCAIX) are developed internally through GMP manufacturing and clinical trials, then monetized via licensing and co-development agreements with global pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Brands
- Philochem: Wholly-owned subsidiary focused on DNA-encoded chemical libraries, radiopharmaceutical research and development, and tumor-targeting diagnostic and therapeutic agents.
Products and services
- Nidlegy Immunocytokine product (L19IL2/L19TNF combination) being developed for the treatment of melanoma and other solid tumors; an MAA has been submitted in the European Union.
- Fibromun (L19TNF) Antibody-cytokine fusion protein (L19TNF) for the treatment of soft tissue sarcoma with lung metastases and other solid tumors; holds EU Orphan Drug Designation.
- Darleukin (L19IL2) Antibody-cytokine fusion protein (L19IL2) used as a targeted immunocytokine therapeutic in Philogen's oncology pipeline, also serving as a component of Nidlegy.
- Dodekin Antibody-cytokine fusion protein candidate in Philogen's pipeline targeting tumor-associated antigens for cancer therapy.
- Dekavil Targeted therapeutic antibody candidate in Philogen's pipeline for the treatment of inflammatory and oncology indications.
- OncoFAP Radio Conjugates (Imaging) Small-molecule FAP-targeting radio-conjugate for PET imaging of solid tumors, leveraging Philogen's proprietary OncoFAP ligand.
- OncoFAP Radio Conjugates (Therapy) Small-molecule FAP-targeting radio-conjugate for radioligand therapy of solid tumors.
- OncoFAP-GlyPro-MMAE (Therapy) FAP-targeting antibody-drug conjugate bearing an MMAE payload for targeted chemotherapy of solid tumors.
- OncoACP3 (Imaging) Radiopharmaceutical diagnostic agent targeting Prostatic Acid Phosphatase (ACP3) for PET imaging of prostate cancer; worldwide rights licensed to RayzeBio/BMS.
- OncoACP3 (Therapy) Radiopharmaceutical therapeutic agent targeting Prostatic Acid Phosphatase (ACP3) for treatment of prostate cancer; worldwide rights licensed to RayzeBio/BMS.
- OncoCAIX Carbonic anhydrase IX (CAIX)-targeting small-molecule agent for imaging and therapy of renal cell carcinoma (kidney cancer).
Quantifiable outcome
- Fibromun is identified as a key drug candidate in development for soft tissue sarcoma with lung metastases market projected to grow during 2026-2036
- +1 more outcomes
Companies that use Philogen
Customer profileSegments2 records
Ideal customer profiles3 records
Philogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Philogen partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- RayzeBio (Bristol-Myers Squibb)corePhilochem AG (Philogen subsidiary) licensed worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio, a Bristol-Myers Squibb company. Deal potential value of up to $1.35 billion plus royalties. Antitrust clearance completed and agreement closed in August 2025.
- Janssen BiotechcorePhilogen S.p.A. entered into collaboration, option and license agreement with Janssen Biotech for therapeutic development.
- AbbViecorePhilogen announced expanded research and development agreement with AbbVie for continued collaboration on therapeutic development.
- Boehringer IngelheimcorePhilogen signed collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia (AML).
- PfizercorePhilogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates (ADCs) and targeted nanoparticles. In January 2016, Pfizer exercised options granted under this agreement for potential development and commercialization of multiple ADCs.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Philogen competitors and assessment
Company assessmentBroad incumbents
- Novartis: Owns Pluvicto and Lutathera, the most commercially successful targeted radiopharmaceuticals in oncology. While a broad incumbent, Novartis's radioligand franchise defines the commercial benchmark Philogen's programs must compete against.
- Bayer: Operates a radiopharmaceutical business (including Xofigo and ongoing pipeline) and has an established oncology therapeutics franchise. As a broad incumbent, it competes for the same pharma partners and licensing counterparties that Philogen targets.
Direct peers
- Lantheus Holdings: US radiopharmaceutical company with both diagnostic imaging agents (e.g., PYLARIFY for PSMA) and a growing radiotherapeutic pipeline, closely comparable to Philogen's combined imaging + therapy radiopharma model.
- Telix Pharmaceuticals: Australian-headquartered radiopharmaceutical company developing targeted imaging and therapy agents for cancer (including prostate cancer PSMA imaging), the most direct comparability to Philogen's OncoACP3 and OncoFAP programs in oncology radiopharmaceuticals.
- Curium Pharma: Global radiopharmaceutical company producing diagnostic and therapeutic radioisotope products across oncology, neurology and cardiology. Direct peer in scale and product category to Philogen's radiopharma business.
- ITM Isotope Technologies Munich: German radiopharmaceutical company developing targeted radionuclide therapies and diagnostics for cancer. Comparable in modality, target indications, and licensing-led go-to-market to Philogen's radiopharma pipeline.
Emerging players
- ADC Therapeutics: Swiss-listed clinical-stage biotech focused on antibody-drug conjugates for hematologic and solid tumors. Comparable emerging biologics developer with similar partnership-driven monetization and pipeline breadth.
- Molecular Partners: Swiss clinical-stage biotech developing DARPin-based targeted cancer therapeutics. Comparable as a Swiss-headquartered, partnership-driven oncology biologics developer with similar size and capital profile.
Regional players
- Bracco Imaging: Italian-headquartered diagnostic imaging company with a strong radiopharmaceutical and contrast imaging portfolio. Direct regional overlap with Philogen in Italian clinical and imaging markets, and competes for similar talent and clinical sites.
Others
- X-Chem: Drug discovery company specializing in DNA-encoded library screening for hit identification, closely analogous to Philogen's DEL-based discovery engine. Comparable as an enabling technology vendor / partner in the DEL ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Philogen social profiles
Digital presencePhilogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Philogen leadership team
Management profileNumber of profiles
Profiles5 records
Philogen subsidiaries and ownership
Company hierarchySubsidiaries1 record
Philogen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Philogen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Philogen
What does Philogen do?
Philogen is a clinical-stage biotechnology company that discovers, develops, and manufactures targeted cancer therapeutics based on immunocytokines (antibody-cytokine fusion proteins), DNA-encoded chemical library-derived small molecules, and radiopharmaceuticals. Its pipeline products (Nidlegy, Fibromun, Darleukin, Dodekin, Dekavil, OncoFAP, OncoACP3, OncoCAIX) are developed internally through GMP manufacturing and clinical trials, then monetized via licensing and co-development agreements with global pharmaceutical partners.
Is Philogen a public or private company?
Philogen is a public company. It is classified as public and is currently operating.
When was Philogen founded?
Philogen was founded in 1996. It employs 101 to 250 people.
Where is Philogen based?
Philogen is headquartered in Sovicille, Italy, in the Europe region.
How does Philogen make money?
Three revenue lines are on record. Pharmaceutical Licensing and Royalties are the primary driver. The others are strategic Research Partnerships and pipeline Product Development.
Who are Philogen's main competitors?
Broad incumbents on record are Novartis and Bayer. Direct peers are Lantheus Holdings, Telix Pharmaceuticals, Curium Pharma and ITM Isotope Technologies Munich. Emerging players are ADC Therapeutics and Molecular Partners. Bracco Imaging is listed as a regional player. X-Chem is listed as an others.
Does Philogen have an API?
No public API is recorded for Philogen.
What industry is Philogen in?
Philogen's product category is Targeted Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 325414 and its SIC code is 2836.